There is growing evidence of antineoplastic properties of metformin (MET) in prostate cancer (PCa). Many observational studies suggested that using MET was associated with improvement in overall survival in PCa patients. MET was reported to be associated with reduction of risk of development of castration-resistant state (CRPC). In addition, when MET was combined to ADT or biclutamide, it augmented the antiproliferative effect of these drugs.
To read this article in full you will need to make a payment
© 2020 European Society for Medical Oncology. Published by Elsevier Inc. All rights reserved.